Risk Factors for Progressive Disease After Immune Checkpoint Inhibitor Therapy in Head and Neck Squamous Cell Carcinoma

Ähnliche Einträge

• Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated CDK4 /6 Pathway
  von: Joo‐Hwan Park, et al.
  Veröffentlicht: (2026)
• Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19 ‐09, CONPELAN Study
  von: Sang Hoon Chun, et al.
  Veröffentlicht: (2026)
• Reducing the Duration of 24‐Hour Multichannel Intraluminal Impedance‐pH Monitoring for Laryngopharyngeal Reflux
  von: Hyun Jee Lee, et al.
  Veröffentlicht: (2025)
• The Small Molecule Inhibitor of the Wnt–β‐Catenin Pathway, CWP232291 , Inhibits Tumor Growth in Preclinical Models of Salivary Gland Adenoid Cystic Carcinoma
  von: Joseph O. Humtsoe, et al.
  Veröffentlicht: (2025)
• Postoperative pain management using an intravenous combination of ibuprofen and acetaminophen compared with acetaminophen alone after thyroidectomy: A prospective randomized controlled trial
  von: Jaesik Park, et al.
  Veröffentlicht: (2024)